Background: People with CD have an increased risk of low bone mineral density,
osteopenia, osteoporosis and vitamin D deficiency. The aim of this the study was to assess …

Aim: To prospectively evaluate efficacy and safety of ADA in pediatric pts with moderate to
severe CD. Patients and Methods: 23 CD pts, median age 16.1 years (range 9 20), naive to …

P523 Efficacy and safety of adalimumab (ADA) therapy in pediatric Crohn's disease (CD)
patients who failed infliximab (IFX): Page 1 Clinical: Therapy and observation S219 ADA …

Results: Data for 347 patients (214 males, age 46.3 years; CAI 7.47) were available; 288
patients were either steroidresistant or steroid-dependent. The proportion of patients with …

Background Intensification of adalimumab (ADL) dosing to weekly 40 mg injections, in
response to low drug levels, has been shown to provide beneficial outcomes in pediatric …

Aim: Although Crohn's disease (CD) is known to be associated with osteoporosis, the
mechanisms through which this association is established remain to be unravelled. This …

Objectives: European Crohn's Colitis Organization (ECCO) and the European Society of
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines recommend …

Purpose: To measure changes in bone metabolism in pediatric patients (pts) with
moderately to severely active Crohn's disease (CD) treated with adalimumab (ADA) enrolled …

Resumen NAVAS-LOPEZ, Víctor Manuel et al. Efficacy and safety of adalimumab in the
treatment of Crohn's disease in children. Rev. esp. enferm. dig.[online]. 2013, vol. 105, n. 10 …

Purpose: To characterize common indications, safety, tolerability, and clinical response to
the use of adalimumab (ADA) beyond one year in a multi-center cohort of pediatric patients …